<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444885</url>
  </required_header>
  <id_info>
    <org_study_id>STELLA</org_study_id>
    <nct_id>NCT01444885</nct_id>
  </id_info>
  <brief_title>Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina</brief_title>
  <acronym>STELLA</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of PletaalÒ(Cilostazol) in Subjects With Vasospastic Angina (STELLA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the efficacy and safety of Pletaal (Cilostazol)&#xD;
      in comparison with placebo for 4 weeks in vasospastic angina patients who have an&#xD;
      insufficient response to Amlodipine (Calcium channel blocker).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel group, Therapeutic&#xD;
      exploratory Study.&#xD;
&#xD;
      The subject who has at least an episode of chest pain weekly despite Amlodipine 5mg once a&#xD;
      day (qd) taking during 2 weeks will have treatment of Pletaal (Cilostazol) or Placebo for 4&#xD;
      weeks. Pletaal (Cilostazol) is taken 100mg oral tablets two times a day (bid) during 2 weeks&#xD;
      after dosing of Pletaal (Cilostazol) 50mg oral tablets bid during 2 weeks. Placebo of Pletaal&#xD;
      (Cilostazol) is used as the control medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change of the chest pain frequency</measure>
    <time_frame>A week before IP dosing and the final a week after IP dosing (average 6weeks)</time_frame>
    <description>Collect the chest pain frequency data related with vasospastic angina episodes by subject diaries.&#xD;
Descriptive statistics (N, mean, standard deviation, minimum, median and maximum) will be presented by treatment group. ANCOVA will be performed between the treatment groups using the baseline (a week before IP dosing) as covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The chest pain frequency, the pain intensity, nitroglycerin consumption of the final a week after IP dosing from a week before IP dosing</measure>
    <time_frame>A week before IP dosing and the final a week after IP dosing (average 6weeks)</time_frame>
    <description>Descriptive statistics (N, mean, standard deviation, minimum, median and maximum) will be presented by treatment group. ANCOVA will be performed between the treatment groups using the baseline (a week before IP dosing) as covariate. The subject who has no chest pain will be regarded as the total pain intensity and the average pain intensity are '0'. The subject who has taken no nitroglycerin will be regarded as taking '0' tablet.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Variant Angina</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Amlodipine</other_name>
    <other_name>Nitroglycerin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female over the age of 20 and under the age of 80&#xD;
&#xD;
          2. Diagnosis of vasospastic angina&#xD;
&#xD;
          3. At least one episode of chest pain weekly during the Amlodipine run in period for 2&#xD;
             weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently taking or has taken Cilostazol within the last 3 month before the screening.&#xD;
&#xD;
          2. Taking oral antiplatelet agents such as Aspirin, Clopidogrel after Amlodipine run-in&#xD;
             period.&#xD;
&#xD;
          3. Oral anticoagulants such as Warfarin within the last a month before the screening.&#xD;
&#xD;
          4. Currently taking any of the following medications or has taken any of the following&#xD;
             medications within the last a week before the screening:&#xD;
&#xD;
               -  Other Calcium channel blockers than Amlodipine&#xD;
&#xD;
               -  Beta-blocker, or Alpha-blocker&#xD;
&#xD;
               -  Oral Nitrate, Nicorandil, except sublingual Nitroglycerin as required(PRN)&#xD;
&#xD;
               -  Vitamin E preparations&#xD;
&#xD;
               -  Estrogens&#xD;
&#xD;
          5. History of Myocardial infarction or Myocardial infarction by vasospastic angina at&#xD;
             screening&#xD;
&#xD;
          6. History of life threatening vasospastic events such as ventricular tachycardia ,&#xD;
             ventricular fibrillation, or syncope&#xD;
&#xD;
          7. History of stroke, intracranial hemorrhage, or Transient Ischemic Attack(TIA)&#xD;
&#xD;
          8. Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper&#xD;
             gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous hemorrhage,&#xD;
             etc.) or such tendency (active peptic ulcer, hemorrhagic stroke within past 6 months,&#xD;
             a case hemorrhage is suspected by wound for surgery within 3 months, proliferative&#xD;
             diabetic retinopathy and uncontrolled hypertension)&#xD;
&#xD;
          9. History of clinically significant hypersensitivity to the substances of Cilostazol,&#xD;
             Amlodipine, Nitroglycerin or dihydropyridine&#xD;
&#xD;
         10. Patients with severe aortic valvular stenosis&#xD;
&#xD;
         11. History of shock&#xD;
&#xD;
         12. Hypotension of diastolic pressure &lt; 90 mmHg at screening&#xD;
&#xD;
         13. History of clinically significant hypersensitivity to the substances of Nitrates&#xD;
&#xD;
         14. Patients with severe anemia of Hemoglobin ≤ 6.5 g/dl at screening&#xD;
&#xD;
         15. History of glaucoma&#xD;
&#xD;
         16. Electrocardiogram(ECG) abnormality precluding interpretation of ST change at screening&#xD;
&#xD;
         17. Congestive heart failure with less than 40% of left ventricular ejection fraction&#xD;
             within the last 3 month before the screening or screening period&#xD;
&#xD;
         18. Atrial fibrillation or valvular heart disease, more than moderate severity&#xD;
&#xD;
         19. Suspected or identified spasm of left main coronary artery, result of coronary&#xD;
             angiography or coronary angiography in the ergonovine induced coronary spasm&#xD;
             provocation test&#xD;
&#xD;
         20. History of Coronary artery bypass graft(CABG) or percutaneous coronary&#xD;
             intervention(PCI)&#xD;
&#xD;
         21. Tachycardia; Heart rate &gt; 100 bpm, at Screening&#xD;
&#xD;
         22. Uncontrolled hypertension, defined as ≥ 160 mmHg systolic or ≥ 100 mmHg diastolic at&#xD;
             Screening&#xD;
&#xD;
         23. Creatinine ≥ 1.5 mg/dL at screening&#xD;
&#xD;
         24. Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3 times the upper limit&#xD;
             of normal (ULN) at screening&#xD;
&#xD;
         25. Platelet &lt; 100,000 mm3 at screening&#xD;
&#xD;
         26. QT prolongation defined as baseline QTc &gt; 450 msec for males or &gt; 470 msec for females&#xD;
             at Screening.&#xD;
&#xD;
         27. Women who have the possible of pregnancy, or positive urine or blood pregnancy test at&#xD;
             screening&#xD;
&#xD;
         28. Women who are not using a reliable method of birth control, who are pregnant, or who&#xD;
             are breast-feeding&#xD;
&#xD;
         29. Drug compliance of Amlodipine &lt; 80% during the Amlodipine run in period for 2 weeks&#xD;
&#xD;
         30. Otherwise judged by the investigator to be inappropriate for inclusion in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June Hong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Yansan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChungNam Univ. Hospital</name>
      <address>
        <city>DaeJeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gyongsang National University Hospital</name>
      <address>
        <city>Jinjoo</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yansan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 27, 2011</study_first_submitted>
  <study_first_submitted_qc>September 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2011</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Variant angina</keyword>
  <keyword>Cilostazol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina Pectoris, Variant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

